- Home
- NEOV vs CRVO Comparison
NEOV vs CRVO Comparison
Compare NEOV & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEOV
- CRVO
- Stock Information
- Founded
- NEOV 2018
- CRVO 2001
- Country
- NEOV United States
- CRVO United States
- Employees
- NEOV N/A
- CRVO N/A
- Industry
- NEOV Industrial Machinery/Components
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- NEOV Miscellaneous
- CRVO Health Care
- Exchange
- NEOV Nasdaq
- CRVO Nasdaq
- Market Cap
- NEOV 72.2M
- CRVO 67.4M
- IPO Year
- NEOV N/A
- CRVO N/A
- Fundamental
- Price
- NEOV $4.52
- CRVO $7.19
- Analyst Decision
- NEOV Strong Buy
- CRVO Strong Buy
- Analyst Count
- NEOV 1
- CRVO 7
- Target Price
- NEOV $7.50
- CRVO $19.33
- AVG Volume (30 Days)
- NEOV 197.3K
- CRVO 160.7K
- Earning Date
- NEOV 05-09-2025
- CRVO 08-08-2025
- Dividend Yield
- NEOV N/A
- CRVO N/A
- EPS Growth
- NEOV N/A
- CRVO N/A
- EPS
- NEOV N/A
- CRVO N/A
- Revenue
- NEOV $4,255,136.00
- CRVO $9,308,215.00
- Revenue This Year
- NEOV $208.50
- CRVO N/A
- Revenue Next Year
- NEOV $128.75
- CRVO N/A
- P/E Ratio
- NEOV N/A
- CRVO N/A
- Revenue Growth
- NEOV 52.64
- CRVO 15.14
- 52 Week Low
- NEOV $1.80
- CRVO $1.80
- 52 Week High
- NEOV $6.11
- CRVO $20.63
- Technical
- Relative Strength Index (RSI)
- NEOV 75.13
- CRVO 54.51
- Support Level
- NEOV $3.10
- CRVO $5.45
- Resistance Level
- NEOV $4.75
- CRVO $7.55
- Average True Range (ATR)
- NEOV 0.35
- CRVO 0.54
- MACD
- NEOV 0.14
- CRVO 0.19
- Stochastic Oscillator
- NEOV 89.94
- CRVO 87.14
About NEOV NeoVolta Inc.
NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.